Special Issue "Aldose Reductase: Functions, Inhibitors and Molecular Mechanisms"
Deadline for manuscript submissions: 31 May 2021.
Since its discovery, aldose reductase (AKR1B1), an enzyme of the aldo-keto reductase family that catalyzes the NADPH reduction of a variety of hydrophilic as well as hydrophobic aldehydes, has been considered a promising target for the treatment of long-term diabetic complications. This enzyme is the first one in the so-called polyol pathway, which converts glucose into fructose. Under hyperglycemic conditions, an exaggerated flux of glucose through the polyol pathway leads to a series of damaging events (e.g., sorbitol accumulation, oxidative stress, protein glycation) involved in the etiology of secondary diabetic complications, such as nephropathies, retinopathies, neuropathies, and cataract. Over the last four decades, a great effort has been devoted to the search of molecules able to inhibit aldose reductase, thus preventing the onset of diabetic complications. Despite the in vitro efficiency of many molecules synthetized as aldose reductase inhibitors, no significant drug development has followed. There may be a number of reasons for such a failure, from the reduced bioavailability of the drug to the onset of unwanted side effects; however, another possible explanation lies on the catalytic features of the enzyme itself, which can reduce toxic alkenals and alkanals, derived from lipid peroxidation processes, thus behaving as a detoxifying enzyme.
In addition to its possible role in the etiology of diabetic complications, another relevant feature of aldose reductase which has emerged more recently is its involvement in inflammation: Several studies have suggested that aldose reductase may play a key role in a number of inflammatory processes through the production of pro-inflammatory molecules. Thus, the inhibition of the enzyme activity may help to control inflammation.
This Special Issue will focus on the functions, inhibition, and molecular mechanisms of aldose reductase and will include reviews and research articles on these topics with the aim of presenting the most recent advances on the features of this multifaceted enzyme.
Prof. Mario Cappiello
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- aldose reductase
- aldo-keto reductases
- polyol pathway
- 4 hydroxynonenal
- aldose reductase inhibitors